Annual Trainee Oncology Meeting (ATOM) 2025

Dr Conroy graduated and completed her early medical training in Newcastle-upon-Tyne and then returned to Manchester and commence her oncology training at The Christie in 2009.

During her time at the Christie she won the learning assessment test at the 2012 ESO Masterclass in clinical oncology - first out of 62 young oncologists from 28 countries. She spent a year as a clinical observer in a large teaching hospital in Sydney, Australia before returning to The Christie to take up a post as a Consultant.

Dr Louise Hanna is a consultant clinical oncologist at the Velindre Cancer Centre, Cardiff where she specialises in gynaecological cancer. She completed her medical training at the University of Cambridge and the University of Oxford before undertaking her clinical oncology training at the Velindre Cancer Centre.

Dr Hanna has been involved with education and training at the RCR since being the trainee representative for Wales. As a consultant, she has been a member of the Clinical Oncology (CO) Specialty Training Board, has served on the CO Curriculum Committee as clinical lead for quality and more recently, worked alongside Dr Karen Tipples as the clinical lead for CO National Recruitment. 

Dr Hanna has experience as Associate Dean (Quality) within Health Education and Improvement Wales and as Assistant Medical Director for Education and Training at Velindre University NHS Trust. She was also the lead editor for the textbook Practical Clinical Oncology (Cambridge University Press).

Read our interview with Dr Hanna and find out what attracted her to the specialty and why she wanted to get more involved with the RCR.

Dr Hanna's tenure as Medical Director, Education and Training, Clinical Oncology at the RCR is 2023-2026.

Professor Hoskin trained in clinical oncology at the Royal Marsden Hospital London and has been a consultant in clinical oncology at Mount Vernon Cancer Centre, Northwood since 1992. Professor in Clinical Oncology in the University of Manchester and Honorary consultant in clinical oncology at the Christie Hospital, Manchester. Research interests focus on radiosensitisation, biomarkers, radiotherapy quality assurance, palliative radiotherapy, and brachytherapy.

Corinne Faivre-Finn is a Professor of Thoracic Radiation Oncology at the University of Manchester and Honorary Consultant Clinical Oncologist. She is an NIHR Senior Investigator. She has numerous professional roles including radiotherapy research lead for Manchester Cancer Research Centre & the CRUK Lung Cancer Centre, Chair of the ESTRO Lung Focus Group and Radiotherapy Chair of the EORTC Lung Group.   Professor Faivre-Finn is also an active member of several national and international research committees including the IASLC Advanced Radiotherapy & Multidisciplinary Clinical Science Committees and the ESTRO clinical committee.  She is Principal Investigator for numerous trials studying radiotherapy in lung cancer and an author of guidelines on the management of patients with lung cancer (ESMO, BTS, EORTC, ERS, ASTRO). She has authored >300 papers including 7 practice changing studies.  

Professor Ananya Choudhury is Chair of Clinical Oncology and Clinical Lead for Advanced Radiotherapy within the Division of Cancer Sciences, University of Manchester as well as Honorary Consultant in Clinical Oncology at The Christie NHS Trust, UK.  Professor Choudhury undertakes research which aims to optimise and personalise radiotherapy using new techniques or imaging technology to deliver high doses of radiotherapy while minimising side effects and predictive biomarkers to determine which patients benefit from different treatments.  Professor Choudhury holds national leadership roles within the Royal College of Radiologists, and works closely with the National Institute of Health and Care Excellence (NICE). Professor Choudhury is currently the Editor in Chief of BMJ Oncology.  

Dr Hudson leads the urology systemic clinical trials clinic at The Christie and is responsible for delivering chemotherapy to urology patients across Greater Manchester. He visits Salford Royal to provide radiotherapy and systemic anti-cancer treatments for prostate and bladder cancer patients.

In addition, he treats penile cancer patients across North West England and North Wales. He is a member of the Drugs and Therapeutics Committee at The Christie and Research Lead for the Greater Manchester Urology Pathway Board.

Research Interest  Dr Hudson is the Chief Investigator for early phase clinical trials investigating the use of new medicines in prostate cancer in collaboration with the Experimental Cancer Medicine Team. He is also local Principal Investigator for various later phase clinical trials involving novel medicines and radiotherapy techniques.

He has a research background in translational science, with a PhD in cancer genomics, and collaborates with multiple lab groups in the Manchester Cancer Research Centre.

Nicky Thorp trained in medicine at the University of Leicester, graduating in 1990. She completed her specialist oncology training at the Clatterbridge Cancer Centre. She was appointed as a consultant clinical oncologist in 2001 at Clatterbridge with subspecialty interests in breast cancer, paediatric radiotherapy and late effects. In 2019 she took up her post at the Christie Hospital in Manchester specialising in photon and proton beam therapy for children. Her research interests are in paediatric tumours and radiotherapy quality assurance. She was previously radiotherapy lead for the NCRI CCL CNS Subgroup and is UK radiotherapy lead for the pan-European SIOP Ependymoma II study.    

Nicky was Medical Director for Professional Practice for Clinical Oncology at the Royal College of Radiologists from September 2021 to August 2024 and and is currently Co-lead for Wellbeing at the RCR. She previously served two terms on the RCR CO Faculty Board.    

Nicky was Associate Medical Director at Clatterbridge between 2010 and 2016. Her roles included clinical lead for the new build Clatterbridge Cancer Centre-Liverpool.    She served two terms on the Children’s Cancer and Leukaemia Group (CCLG) Executive and is past chair of the CCLG Radiotherapy and Neuro-oncology Groups.

I am a Consultant Clinical Oncologist with site speciality interest in Oesophago-Gastric, HepatoBiliary and pancreatic cancers. I am also the Director of Postgraduate Medical Education at the Christie NHS FT and a member of the RCR Clinical Oncology STB. I've been a member of the trial management group and RTQA subgroup for a few pancreatic cancer radiation therapy trials UK trials, as well as acting as clinical lead on the pancreatic cancer national audit and GIRFT. I've part of the group that developed and implemented the PACT UK radiology synoptic reporting tool for UK pancreatic MDTs.

As one of the co-applicants for the successful NHS E-commissioning for Stereotactic Ablative pancreatic cancer for locally advanced pancreatic cancer, I am also supporting the UK wide roll out for SABR for this indication.

Additionally, I work as the Director of post grad training at the Christie. As a first-generation immigrant, I have personal experience in the issues relating to EDI in training and education.

My interests also include addressing issues of neurodiversity, which is becoming increasingly prevalent in medical education. To contribute, I am leading on work examining this topic which I hope will contribute towards our understanding of this amongst clinical oncologists globally.

Dr David Woolf has specialised in breast and lung cancer care at The Christie since 2015. A graduate of the University of Birmingham, he completed advanced oncology training at top London hospitals. Dr Woolf manages radiotherapy, chemotherapy, and targeted therapies, with a focus on imaging and bone metastases. He has numerous peer-reviewed publications, runs clinics at multiple hospitals, and contributes to medical education, including training at The Christie and Royal College of Radiologists.